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Bronchial thermoplasty (BT) delivers targeted radiofrequency
energy to bronchial airway walls and results in the partial
ablation of the airway smooth muscle that is responsible for
bronchoconstriction. It is approved for the treatment of severe
persistent asthma. Multiple, large clinical trials including a
recent “real-world” study demonstrate significant improvements
in asthma-related quality of life, reduction in asthma
exacerbations, emergency department visits, and hospitalizations
after BT that is sustained out to 5 years. In this article, we review
the state of the art of BT treatment in severe persistent asthma
and share a decade of BT research and clinical experience. We
share our personal experience and introduce the three “I”s
(identification, implementation, and intense follow-up) that we
believe promote successful patient outcomes and help build a
successful BT program.  2019 The Authors. Published by
Elsevier Inc. on behalf of the American Academy of Allergy,
Asthma & Immunology. This is an open access article under the
CC BY-NC-ND license (http://creativecommons.org/licenses/by-
nc-nd/4.0/). (J Allergy Clin Immunol Pract 2019;7:71-80)
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Mayse et al1 published their expert opinion and clinical pearls
for bronchial thermoplasty (BT) in 2007. Since their publication,
BT has been performed across multiple countries with more than
6000 patients treated worldwide. The vast expansion in BT
clinical experience resulted in reassurance of safety and addressed
the initial fears of what this technology would do to our patients. It
has also led to an improved BT technique, patient and BT team
preparation, interdisciplinary planning, and performance of BT.
Our state-of-the-art review offers an updated perspective and
clinical pearls from experts at various centers of excellence for BT.
WHAT IS BRONCHIAL THERMOPLASTY?
Since approval by the US Food and Drug Administration
(FDA) in 2010, BT endures as a proven and safe procedure
indicated for the treatment of severe persistent asthma that is not
controlled with high-dose inhaled corticosteroids (ICSs) and
long-acting b2-agonists (LABA). The procedure decreases
hypertrophied airway smooth muscle (ASM) that contributes to
airway hyperreactivity in severe asthmatics.2,3 No other treat-
ments, including biologics for severe asthma, directly alter the
anatomy of bronchial smooth muscle. BT consists of tightly
controlled delivery of radiofrequency (RF) thermal energy to the
airway wall via the Alair catheter electrode. As a result, BT
decreases ASM mass, bronchial nerve endings, and neuroendo-
crine cells.4 RF electrical energy is systematically applied to air-
ways between 3 and 10 mm in diameter throughout the
tracheobronchial tree. The delivery of the energy during BT uses
continuous feedback to tightly control the degree of tissue
heating to avoid bronchial perforation, scorching, and stenosis.
CURRENT STATE OF THE EVIDENCE
BT underwent extensive preclinical studies that demonstrated
unequivocal attenuation of airway narrowing in response to
endobronchial installation of methacholine using dog airways.
Evaluation of the airway histology in the dogs revealed that the
ASM was reduced by 40% to 60%.5 The first randomized
controlled trial of BT (Asthma Intervention Research [AIR] 1)
demonstrated significant improvements in asthma symptom-free
days and asthma-related quality of life as measured by the
Asthma Control Questionnaire (ACQ) (1.2  1.0 vs 0.5 
1.0; P ¼ .001) and the Asthma Quality of Life Questionnaire
(AQLQ) (1.3  1.0 vs 0.6  1.1; P ¼ .003). There were no
differences in forced expiratory volume in 1 second (FEV1) or
airway hyperresponsiveness (defined by a provocative concentra-
tion of methacholine required to lower the FEV1 by 20% [PC20]
of less than 8 mg per milliliter).6 A second trial was designed to
evaluate BT in more severe symptomatic patients (Research in
Severe Asthma [RISA]). Prebronchodilator FEV1 was 62.9% of
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ACQ- Asthma Control Questionnaire
AQLQ- Asthma Quality of Life Questionnaire
ASA- American Society of Anesthesia
ASM- Airway smooth muscle
ATS- American Thoracic Society
BT- Bronchial thermoplasty
ERS- European Respiratory Society
ETT- Endotracheal tube
FDA- Food and Drug Administration
FEV1- Forced expiratory volume in 1 second
ICS- Inhaled corticosteroid
LABA- Long-acting b2-agonists
LMA- Laryngeal mask airway
MAC-Monitored anesthesia care
RF- Radiofrequency
predicted for the BT group and 66.4% of predicted in the
control group. BT subjects had a significant improvement in
FEV1 (14.9  17.4 vs 0.9  22.3; P ¼ .04) and in ACQ
(1.04  1.03 vs 0.13  1.00; P ¼ .02).7 While compelling,
these trials were not blinded and the world’s first sham bron-
choscopy controlled trial (AIR2) was designed in consultation
with the FDA. This multicentered, double-blind, sham bron-
choscopy controlled trial enrolled a total of 288 patients to BT in
a 2:1 fashion. This pivotal trial demonstrated a significant
improvement in the AQLQ score as well as a reduction in the
frequency of severe asthma exacerbations, emergency department
visits, and days lost from school or work in the year after BT.8
On the basis of this trial, BT was approved by the FDA for
the treatment of severe persistent asthma not controlled with
high-dose ICS and LABA. FDA approval was made contingent
on the performance of a postmarketing study (the PAS2 study).
The 3-year follow-up results of this trial were recently published,
confirming the results of the pivotal AIR2 study. As a registry
study, it was not randomized or controlled and AQLQ scoring
was not performed. However, it did demonstrate a reduction in
severe exacerbations, emergency department visits, and hospi-
talizations by 45%, 55%, and 40%, respectively.9
BT is conceptually straightforward; however, achieving a
successful outcome and building a successful BT program are
not. The bronchoscopist should at minimum be trained and
complete the BT curriculum as provided by the manufacturer.
Although the bronchoscopist’s skill and experience are of para-
mount importance, individual patient outcome and long-term
program success are highly dependent on other factors, and a
multidisciplinary approach to patient selection, patient prepara-
tion, patient management, postoperative care, and careful follow-
up is essential.
According to the latest 2014 American Thoracic Society (ATS)/
European Respiratory Society (ERS) task force on severe asthma,10
it was recommended that access to BT should not be limited as a
form of therapy11 but be performed in the context of a registry or
clinical study; although we agree that all BT centers should keep
track of their patient outcomes for quality control purposes, these
same recommendations also pose an undue burden on the
nonacademic practicing pulmonologist. There is a new ATS/ERS
workshop, but it is unclear if BT will be readdressed at this time.
The updated guidelines outlined here are based on the 2018
Global Initiative for Asthma recommendations and the expertise of
the authors and their combined 34 years of experience in BT.
BRONCHIAL THERMOPLASTY PROCEDURE
Overview
A complete BT procedure requires 3 bronchoscopy sessions,
each lasting less than 1 hour, spaced approximately 2-3 weeks
apart.5,12 BT is performed during bronchoscopy withmost patients
undergoing moderate or deep sedation. All accessible airways (be-
tween 3 and 10 mm) distal to the mainstem are treated under
bronchoscopic visualization with the right middle lobe typically
being avoided due to concerns of right middle lobe syndrome.13
Although not recommended by the manufacturer, various sites
have safely and successfully performed BT in the right middle lobe
(RML)with no reports of BT-induced rightmiddle lobe syndrome.
Moving the Alair catheter from distal to proximal along the length
of the visualized airway, contiguous and nonoverlapping activations
are performed systematically from airway to airway.
Equipment
BT is performed using the Alair Bronchial Thermoplasty
System that delivers RF energy—a combination of magnetic and
electrical energy (electromagnetic energy). The system comprises
the Alair RF Controller and the flexible Alair Catheter, a single
use device with an expandable electrode array attached at one end
and a deployment handle at the other. Under direct visualization
through the working channel of a high-frequency compatible
flexible bronchoscope, the electrode array is introduced and
expanded to contact the airway walls. Only when the electrodes
are appropriately contacting the airway walls, will activation of
the Alair RF controller result in RF energy being delivered. RF
energy is transferred from the electrode through the airway wall
and is converted to thermal energy when absorbed preferentially
by high-resistance tissue such as smooth muscle. With each
activation, the Alair RF controller delivers the correct intensity
and duration of RF energy. The controller also monitors the
system, ensuring that energy is not delivered unless all accessories
are properly connected. If activation is attempted while the
electrode array is not in proper contact with the airway wall, a
specific audible error sequence is sounded. A standard adhesive
gel-pad patient return electrode is affixed on the patient and
connected to the controller to provide a complete circuit. BT is
best performed with an RF-compatible bronchoscope with an
outer diameter of 4.9 to 5.2 mm and a minimum 2.0-mm
working channel. Larger-diameter therapeutic bronchoscopes
are not required and may limit access to airways, whereas
thinner-diameter bronchoscopes are not usually necessary, are
TABLE I. Clinical pearls—equipment
 Adhesive gel-pad return electrodes should not be placed on regions
of the body that contain a lot of hair or excessive fat. Placing the
gel-pad on a hairy/fatty region of the body could result in higher
impedance. The higher system impedance could potentially trigger
the high-energy 120J safety cutoff more often. This could result in a
less effective treatment of the airway smooth muscle. Ideally, the
adhesive gel-pad should be placed on areas of high muscle content
(ie, back) with minimal hair (shaving may be required) and not on
fatty regions of the body. Perform BT with a 2.0 working channel
scope
 The Alair BT system is the only FDA-approved equipment for BT
BT, Bronchial thermoplasty; FDA, Food and Drug Administration.
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more difficult to navigate, and may have a working channel that
is too small in diameter (Table I).
Technique
A complete treatment of BT consists of 3 separate bronchos-
copy sessions, each separated by approximately 2 to 3 weeks.
Treatments are divided tominimize the risk of inducing an asthma
exacerbation of diffuse airway edema and inflammation that might
occur if the entire tracheobronchial tree is treated in 1 session. The
first BT treatment is performed in the right lower lobe, the second
in the left lower lobe, and the final in both the right upper and left
upper lobes.12 During all prior clinical trials, the right middle lobe
was not treated due to concerns of inducing right middle lobe
syndrome. Of note, the lingula was treated. Longer-term studies
have not seen an increase in bronchiectasis. The concerns for RML
syndrome with BT have not been adequately studied.14 As a result
of this theoretical concern with evidence of consistently low
ventilation defects in the right middle lobe via hyperpolarized
magnetic resonance imaging studies, various BT centers have
safely and successfully treated the RML.15
We recommend that during second and third bronchoscopy
sessions, the previously treated BT airways be inspected to ensure
proper healing before proceeding with the planned BT proced-
ure. If the previously treated airways appear to have considerable
inflammation (ie, significant erythema, edema, friable mucosa,
narrowing of airway), consideration should be given to post-
poning the current treatment. Postponement of the BT pro-
cedure due to considerable airways inflammation is not common
and should be tailored to the patient’s clinical and airway find-
ings. After a complete airway inspection, the bronchoscope is
navigated to the targeted region of the lung. The bronchoscopist
then formulates a sequential order in which airways will be
accessed and treated and communicates the plan to his/her
assistant. Having an organized treatment plan is critical to the
completion of a proper and safe BT treatment session. A sys-
tematic approach working from distal to proximal, superior to
more inferior, or from right to left, in a methodical organized
fashion ensures that all regions are treated appropriately while
minimizing the error of treating the same airway twice. Within
each segment, the subsegmental airways should be properly
explored and treated in a systematic manner. Although seemingly
straightforward, it is striking how dramatically and rapidly the
airways can change due to edema and bronchospasm, dis-
orienting even experienced bronchoscopists.
The Alair catheter is introduced into the working channel of
the bronchoscope and advanced until the distal end is in view
(Figure 1) within the targeted airway. The catheter is then
expanded until the 4 electrode array wires are in contact with the
airway wall. Proper contact of the electrodes is necessary for
complete activation. Pressing and releasing the controller foot-
switch will initiate activation, and provided there is proper
contact and there is no cancellation, the entire 10-second treat-
ment cycle will be completed. Depressing the footswitch before
completion of the treatment cycle will cancel and prematurely
terminate the treatment—and sound the error sequence. After
each activation, the electrode array should be partially collapsed
and repositioned proximally 1 black line (5 mm) (Figure 1). The
bronchoscopist should pay careful attention not to overlap the
previous activation site. A detailed road “map” of the airways can
assist in keeping track of the progression of treatments and assist
in minimizing errors for each session (ie, treating the same airway
twice). A recent study performed by Langton et al16 described
the importance of delivering the sufficient number of activations
and the positive effect on clinical response. Using a regression
equation, they recommend 40 activations to each of the lower
lobes and 60 activations to the combined upper lobes to achieve
an improvement in ACQ-5 score of 0.5 units. Although further
validation studies are necessary, the BT proceduralist should be
mindful that varying activations can significantly affect patient
outcomes.16 There are situations in which one of the electrodes
on the Alair catheter becomes inverted or mucous buildup
obscures visualization (Figure 2). When these problems are
encountered, the Alair catheter should be completely removed
from the bronchoscope, the electrode gently reshaped and
cleaned, and the bronchoscope irrigated (Table II).
PATIENT SELECTION
Patients should be rigorously screened to (Figure 3): (1)
confirm a correct diagnosis of asthma (includes phenotyping), (2)
verify criteria for severe persistent asthma despite adherence to
appropriate pharmacologic and nonpharmacologic interventions
(at minimum high-dose ICS and LABA), (3) review and address
comorbidities that could affect asthma control (eg, gastroesoph-
ageal reflux disease [GERD], postnasal drip, obstructive sleep
apnea [OSA], smoking, vocal cord dysfunction), (4) reinforce
medication adherence and proper inhaler technique, and (5) rule
out contraindications to BT (ie, implantable electronic device,
under 18 years of age, previously treated with BT). Although
caution is advised in treating patients with an FEV1 < 65% of
predicted, our clinical experience and case series indicate that
patients with a mean FEV1 of 37% could safely undergo and
benefit from BT17(Tables III and IV).
PATIENT MANAGEMENT
The success of BT is dependent not only on proper patient
selection but also on multiple other dynamic variables. The tech-
nical skill of the bronchoscopist and careful patient management
FIGURE 1. Alair catheter.
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during and after the procedure are both of great importance in
ensuring patient safety and successful BT outcomes. It is therefore
of paramount importance that the BTbronchoscopist complete the
proper training from the manufacturer and that the BT team
receive appropriate education and training. Proper analgesia,
topical anesthesia, and anxiolytics are critical in providing comfort
and reducing excessive cough and patient movement. The
approach described will not only facilitate procedure efficiency but
also increase overall patient satisfaction with the procedure.
PATIENT PREPARATION AND PREMEDICATION
As with other medical procedures, the risk and benefits of
bronchoscopy, BT, and sedation should be fully discussed with
the patient. To mitigate the risk of an asthma exacerbation from
postprocedure inflammation of the treated airways, patients
should be given prophylactic prednisone or the equivalent at a
dose of 50 mg/day for the 3 days before the procedure, the day of
the procedure, and the day after the procedure.8 In the days
preceding each procedure, the asthmatologist and/or BT-certified
bronchoscopist should ensure that the patient:
 Has not had a respiratory infection in the days preceding the
procedure
 Has not had a recent asthma exacerbation requiring oral cor-
ticosteroids within the last 14 days
 Has started systemic steroids as directed.
On the day of each procedure, reevaluation is necessary to
ensure that the patient continues to be a good candidate for BT.
Spirometry is performed to ensure that the patient is at his or her
established baseline and to provide an FEV1 benchmark for
comparison with the post-BT FEV1. Postponement of the pro-
cedure should be considered if any of the conditions listed in
Table V applies. We also recommend that physicians follow their
institution’s established prebronchoscopy guidelines.
Supraglottic topical anesthesia
When performing BT under moderate sedation or monitored
anesthesia care (MAC), the transnasal bronchoscopic approach
tends to cause less gagging and fewer secretions, and is safe and
well tolerated. Applying topical lidocaine jelly or liquid to the
nostril(s) will assist in achieving an anesthetized and lubricated
nasal passage. If there are concerns with epistaxis, phenylephrine
or oxymetazoline spray or topical cocaine may be used.1 Supra-
glottic topical anesthesia is not usually required for deep sedation
or general anesthesia. Transoral with moderate sedation or MAC
and laryngeal mask airway (LMA) are better tolerated in patients
with a history of nasal congestion and chronic sinusitis. Trans-
nasal or transoral approaches are viable options depending on the
individual patient and the BT bronchoscopists experience and
comfort level.
Anesthetizing the hypopharynx can be effectively achieved by
having the patient gargle 5 mL of 2% lidocaine. An alternative or
an adjunct to gargling lidocaine is to aerosolize the posterior
pharynx with 1% to 2% lidocaine. Regardless of the technique,
anesthetizing the posterior pharynx will assist in not only
diminishing the patient’s gag reflex but also systemic sedatives.
Careful attention to the amount of lidocaine administered and
mindfulness of systemic absorption of lidocaine will assist in
decreasing the likelihood of lidocaine toxicity (Table III).
Vocal cord and subglottic topical anesthesia
After anesthetizing the patient’s upper airway, the bronchos-
copist should promptly apply topical anesthesia to the vocal cords
and bronchial tree. At the vocal cord level, 1% lidocaine can be
applied in 2-mL aliquots until the patient appears to be
comfortable with minimal coughing. The patient’s sedation level
and tolerance of the procedure should be closely monitored.
Often, providing additional anxiolytic or antitussive medications
can improve patient comfort. Reapplication of local anesthetic 30
to 40 minutes into the procedure is often required to reduce
cough.20
Doses of lidocaine totaling up to 600 mg or 8.2 mg/kg have
been found to be safe in asthmatics undergoing bronchoscopy.21
Patients should be continuously monitored for signs and symp-
toms of lidocaine toxicity.22,23 BT through an LMA is safe,
acceptable, and preferable as endotracheal tube (ETT) can cause
bronchospasm. When an ETT is placed, 2% or 4% lidocaine can
be sprayed onto the vocal cords at the time of endotracheal
intubation. A minimal 7.5 ETT is acceptable, but 8.0 is
preferred (Table VI).
FIGURE 2. Inverted electrode array.
TABLE II. Clinical pearls—technique
 Some patients require more than 2-3 wk to recover. Adequate time
should be allowed for healing before the next BT procedure
 While in the airway and before activating the Alair catheter,
verification of the proposed targeted site for the current BT session
by the bronchoscopist to the BT assistant and nursing staff helps
assure treatment of the correct site
 Authors at various sites have moved beyond direct end catheter
visualization and advance the catheter until resistance is met; the
Alair catheter is then repositioned back 5 mm before the first
treatment is initiated with contiguous activations described above
 When cleaning the electrode array, vigorously shake it within a
bath of room temperature saline as cooling of the catheter wires may
cause malfunction
 After completion of the BT procedure, consider applying
lidocaine through the bronchoscope to the treated regions to lessen
postprocedural cough and pain (lidocaine limit of 600 mg or
8.2 mg/kg)
BT, Bronchial thermoplasty.




BT can be performed under moderate sedation, deep seda-
tion, or general anesthesia. Moderate sedation, also formerly
known as conscious sedation, is defined as sedation under
which a patient is able to respond purposefully to either verbal
commands or with light tactile stimulation. Deep sedation is
when a patient cannot be easily roused but is still able to
respond purposefully with repeated or noxious stimuli. General
anesthesia is a state of unconsciousness in which the patient is
unarousable to painful stimuli, has an impaired ability to
protect and maintain the airway, and may have inadequate
spontaneous ventilation and/or cardiovascular function. Patients
undergoing any form of sedation need to be closely observed
and be under the care of the appropriate and necessary staff.
The staff must possess the skills and qualifications needed to
address reasonably anticipated complications.24,25 By definition,
TH2 Low TH2 High 
Consider BT for those who have failed 
biologic therapy for 3 months 
Checkpoint 
Labs: 
• CBC with diff 
• IgE 
• RAST or Regional serum allergen panel  
Tests: 
• Pulmonary funcon test with bronchodilator 
challenge (should include lung volume and 
DLCO)
• Consider CXR or CT scan if an overlapping 
pulmonary disease is suspected
Co-morbidity 
Exacerbaon Treat & Manage 
Co-morbidies (i.e. GERD) 
Check Point 
Labs and Tests  
YES 
Determine if this is an asthma exacerbation or 
exacerbation of co-morbidity? 
• Review paent’s past medical history 
• Discuss with paent if they were recently given a 
new medical diagnosis
Connue with current 
therapy for at least 3 months 
or Step-down asthma 
therapy aer 3 months of 
control 
Does the patient have the following? 
• Worsening breathlessness 
• Increased Wheezing 
• Night me coughing/awakenings 
• Increased use of rescue inhaler  
• Recent oral prednisone burst 





Repeat Check Point Labs 
CBC with diff & IgE 
(if previous was >3 months) 
Eos ≥400/μL 
Reslizumab 






Atopy with elevated IgE 
Omalizumab 
Consider refractory to Standard Asthma Treatment: 
• If ACT < 19 aer 3 months, or 
• Unable to wean off prednisone, or 
• >2 admissions to ED again or hospital within 4 months 
Review Check Point Labs
FIGURE 3. Asthma algorithm. ACT, Asthma Control Test; CBC, complete blood count; CT, computed tomography; CXR, chest X-ray;
DLCO, diffusing capacity of the lungs for carbon monoxide; ED, emergency department; Eos, eosinophils; GERD, gastroesophageal reflux
disease; RAST, radioallergosorbent test.
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patients undergoing BT are an American Society of Anesthesia
(ASA) class III or greater, and although the presence of an
anesthesiologist should be considered for ASA class III, it
certainly is not required. In the absence of an anesthesiologist,
the BT physician (or assisting physician) must anticipate and be
ready and able to manage procedural or sedation complications,
including severe asthma exacerbations, status asthmaticus, res-
piratory failure, and the need for endotracheal intubation and
mechanical ventilation.
The main objective of BT under moderate sedation is to
maintain an adequate spontaneous ventilatory drive while
providing appropriate anxiolysis and analgesia. Patient comfort
is paramount, as patients will need to be willing to return for a
second and third procedure. Achieving a steady state of
adequate analgesia and sedation with minimal cough requires
frequent reassessment and personalization for each individual
patient. Sedation is commonly achieved using a combination of
a short-acting benzodiazepine and a narcotic. Although there is
no clear consensus for BT, some authors suggest using mid-
azolam, diphenhydramine, and fentanyl, whereas others have
safely achieved moderate sedation with propofol. Midazolam is
a fast-acting benzodiazepine with a short half-life. The onset of
effect is typically between 1 and 3 minutes, with an average
half-life of 2 hours. Midazolam also has the ability to produce
antegrade amnesia, anxiolysis, with an underlying anticonvul-
sant effect. Propofol potentiates gamma-aminobutyric acid
(GABAA) receptors increasing chloride ion conductance,
resulting in inhibitory postsynaptic currents and ultimately
inhibition of neuronal activity; it has a short initial distribution
half-life of 2 to 8 minutes and is rapidly metabolized in the
liver.26 Fentanyl is known for its potent analgesic properties,
but it also has helpful sedative and antitussive properties. Onset
of action for fentanyl is typically between 2 and 4 minutes with
a peak effect at approximately 10 to 15 minutes; the average
half-life ranges from 30 to 60 minutes. Additional doses are
recommended if patients continue to experience pain or are
excessively coughing. Maintaining appropriate analgesia and
sedation while minimizing on cough is the main objective for
fentanyl.
TABLE III. Patient selection
 Adults diagnosed with severe asthma as defined:10,18
B Alternative diagnoses to asthma have been excluded
B Comorbidities have been treated and controlled
B Triggers have been removed
B Compliance with treatment regiments have been verified
and checked
B Symptomatic despite treatment with stable maintenance
medication (ie, high-dose inhaled corticosteroids and
long-acting b2-agonist)
B Asthma that requires treatment with guidelines suggested
medications for GINA19 step 4-5 asthma for the previous year or
systemic corticosteroids for 50% of the previous year to prevent
uncontrolled or which remains uncontrolled despite this therapy
 Caution with prebronchodilator FEV1 <60% predicted—
experienced BT centers may use lower cutoff
 Able to undergo bronchoscopy safely
 No internal pacemaker or neurostimulator
BT, Bronchial thermoplasty; FEV1, forced expiratory volume in 1 s; GINA, Global
Initiative for Asthma.
TABLE IV. Clinical pearls—patient selection
 Patients with persistent asthma symptoms while currently on
biologic therapy should be considered to undergo BT
(or alternatively, “current or past asthma biologic therapy does not
preclude BT”)
 Consider environmental factors at the time of BT (ie, severe cold,
forest fires, regional epidemic illness, eg, influenza) that could result
in a severe exacerbation after BT and if necessary perform BT at
another time
 Perform BT earlier in the week to ensure ample time for follow-up
and assistance if needed from the BT team
 Patients with multiple comorbidities, near fatal asthma, or who
have to travel great distances to receive treatment may benefit from
staying overnight locally but should rarely need to be admitted
BT, Bronchial thermoplasty.
TABLE V. Day of bronchoscopy
Postponement of BT should be considered if any of the following
criteria is present:
 Recent asthma exacerbation requiring oral corticosteroids with
completion of oral steroids less than 14 d before BT
 Active respiratory infection or other clinical signs of instability the
day of or days preceding BT
 Prophylactic prednisone or prednisolone was not started 3 d before
BT
 Increase in asthma symptoms within the last 48 h requiring
4 puffs/d over the pretreatment usage
 SpO2 less than 90% on room air
 During bronchoscopy, airways are extremely edematous or inflamed,
or there are excessive, purulent/tenacious airway secretions
 FEV1 on the day of the procedure is <20% of established baseline
FEV1
 Inability to complete the procedure due to excessive coughing,
excessive secretions, and tortuous anatomy
 Bronchoscopist discretion to postpone the BT procedure
BT, Bronchial thermoplasty; FEV1, forced expiratory volume in 1 s.
TABLE VI. Lidocaine toxicity signs and symptoms
 Lightheadedness







TABLE VII. Clinical pearls—sedation
 The decision to pursue moderate or deep or general sedation is
partially dependent on resources available at each individual BT
center
 Evaluation of the patient’s comorbid conditions should also factor
in the decision on the appropriate sedation. For example, the
profoundly obese with type IV airways are less ideal for moderate
sedation and tend to benefit from an endotracheal tube. The large
abdomen, and the position of the patient supine, can make lower
lobe activations difficult secondary to atelectasis that can be
alleviated with positive pressure and PEEP.
BT, Bronchial thermoplasty; PEEP, positive end-expiratory pressure.
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Deep sedation and general anesthesia require the presence of a
second dedicated physician, usually an anesthesiologist. MAC,
LMA, and endotracheal intubation with or without mechanical
ventilation are available options. Total intravenous sedation with
propofol and limited doses of remifentanil and midazolam, with
or without neuromuscular blockade, provides nearly ideal patient
comfort and makes for a fast, efficient, and safe procedure. These
short-acting agents when combined with neuromuscular blocker
reversal agents promote fast recovery and allow the patients to
fully participate in their postprocedure spirometry.
Avoidance of “drying agents” is highly recommended for 2
reasons: (1) atropine and glycopyrrolate, when administered
before bronchoscopy, do not produce a clinically meaningful
improvement in lung function or decrease in bronchial secre-
tions,27 and (2) some authors have found it more difficult to clear
secretions after bronchoscopy (Table VII).
POSTPROCEDURAL CARE
Post-BT respiratory adverse effects should be expected and
discussed. As anticipated, increases in respiratory-related adverse
effects were seen as patients with higher severity of disease were
treated; this was observed from AIR to RISA and from AIR2 to
PAS2. Severe exacerbations were noted to be greater in the PAS2
study compared with the AIR2 (55.8% vs 40.5%) and emer-
gency department visits (15.8% vs 5.3%). The 2 most common
respiratory adverse events during and after BT treatment periods
in the AIR2 trial were asthma symptoms (ie, cough, nocturnal
awakenings) (52.1% vs 27.3%) and upper respiratory tract in-
fections (20.0% vs 29.9%)8 (Table VIII).
BT postprocedural care should in general follow institutional
guidelines for routine postbronchoscopy care. Patients should be
carefully monitored throughout recovery and discharged only
when vital signs are stable, mental status has returned to baseline,
the patient is able to swallow liquids, and spirometry is accept-
able. We routinely administer nebulized bronchodilators as
needed for symptom control during recovery and before per-
forming postprocedure spirometry. Admission should be
considered for any patient whose post-BT FEV1 is <80% of
their pre-BT FEV1 that day.
Postprocedural education to patient and family is very helpful
to alert them of the increase and worsening of respiratory
symptoms after BT (Figure 5). Symptoms usually present within
1 week of BT with resolution on average within another 1 week.
Some patients have reported peak respiratory-related symptoms
48 hours after the procedure with resolution also within 1 week.
The potential for a postprocedural asthma exacerbation is highest
during the first 7 days, and it is recommended that patients be
contacted 24 hours, 48 hours, and 7 days after the procedure to
assess their respiratory symptoms. Increased coughing is not
uncommon and when not excessive can be beneficial when it
augments the clearance of excessive mucus production. We find
that the routine use of an intrapulmonary percussive device
(acapella device, Aerobika, Flutter valve) at 30 exhalations 3
times a day combined with the routine use of nebulized bron-
chodilators 3 to 4 times a day for the first few days after BT helps
airway clearance and prevents severe mucous plugging. Radio-
graphic abnormalities after BT are common but usually resolve
spontaneously.28 A chest radiograph should be obtained if the
patient has persistent or severe respiratory symptoms to rule out
pneumonia or lung collapse. Symptomatic patients with lung or
lobar collapse may benefit from hospitalization for chest phys-
iotherapy and/or bronchoscopy for mucus plug removal. A BT
aftercare handout can assist patients by addressing concerns on
what to expect after BT, emergency medications that they should
already have at home, when and who to call for help during and
after business hours (Figure 5; Table IX).
DISCUSSION
BT is a validated and proven therapy for patients with severe
persistent asthma that is not controlled despite high-dose ICS
TABLE VIII. AIR2 respiratory adverse events selected AEs with >3% incidence and difference between groups
Adverse event
Treatment period (w12 wk) Posttreatment period (w46 wk)
BT (N [ 190)
%
Sham (N [ 98)
%
BT (N [ 187)
%
Sham (N [ 98)
%
Asthma (multiple symptom) 52.1 38.8* 27.3* 42.9
Wheezing 15.3 6.1* 4.3 3.1
Atelectasis 4.7 0* 0 0
Hemoptysis 3.2 0* 0 0
Lower respiratory tract infection 7.9 2.0* 3.2 6.1
Upper respiratory tract infection 20.0 11.2* 29.9 25.5
Nasopharyngitis 4.7 7.1 10.7 5.1*
Throat irritation 4.7* 12.2 1.1 3.1
AE, Adverse event; BT, bronchial thermoplasty.














FIGURE 4. i3 key points to ensure successful BT outcomes. This
figure stresses the importance of identifying the correct patient
for BT. BT, Bronchial thermoplasty.
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and LABA. The clinical effectiveness of BT is suspected to go
beyond the demonstrated ability to decrease ASM, supporting
the complex relationship between ASM and the airway inflam-
matory cascade.2,3 The most recent real-world BT clinical trial of
severe persistent asthmatics (PAS2) by Chupp et al9
demonstrated that despite having more severe asthmatic sub-
jects, at 3 years after BT, a substantial percentage of PAS2
subjects had significant decreases in severe exacerbations, emer-
gency department visits, and hospitalizations by 45%, 55%, and
40%, echoing the earlier AIR2 results. PAS2 was able to
FIGURE 5. Example of bronchial thermoplasty (BT) aftercare patient handout.
J ALLERGY CLIN IMMUNOL PRACT
JANUARY 2019
78 TAN ETAL
demonstrate the real-world efficacy of BT in a more severe
asthmatic population.8,9 Replication of these successful outcomes
is dependent on the three “I”s: (1) identifying the appropriate
patient, (2) implementing the proper BT technique (including
sedation and anesthesia), and (3) intense postprocedural care and
follow-up (Figures 4 and 6).
Identify the appropriate patient
BT is approved for the treatment of severe persistent asthma
that is not controlled despite high-dose ICS and LABA; however,
properly identifying these patients is not straightforward. The
proliferation of therapeutic options for severe asthma has
increased the importance of proper evaluation and verification of
patients presenting with asthma-like symptoms. Severe asthma
had been defined by the 2014 International ERS/ATS task force,
as asthma that requires treatment with high-dose ICSs plus a
second controller and/or systemic corticosteroids to prevent
asthma from being uncontrolled or remains uncontrolled despite
this therapy.10 The definition for uncontrolled asthma includes
persistent poor asthma symptom control, frequent severe exac-
erbations, or one serious exacerbation resulting in hospitalization
or intensive care unit admission or mechanical ventilation in the
previous year or airflow limitation. Because asthma has no one
specific defining characteristic symptom (eg, wheezing, cough,
chest tightness, breathlessness), it is imperative that for each
individual patient with uncontrolled asthma, we explore and
question whether the diagnosis is correct and whether there are
uncontrolled underlying comorbidities. Investigating other
plausible etiologies that mimic or result in uncontrolled asthma
(ie, inhaler technique, tobacco smoke avoidance, GERD, rhinitis,
etc.) remains a cornerstone of asthma control evaluation and
should be dynamically reviewed, especially if the patient con-
tinues to be refractory to all therapy.
Implementing proper bronchial thermoplasty
technique
Favorable BT results are also determined by the techniques
used and interdisciplinary pre- and post-BT care. BT is a com-
plex bronchoscopic procedure that requires proper training and
completion of the BT curriculum from the manufacturer of the
Alair Bronchial Thermoplasty System. Success of the procedure
is dependent on the technique and assuring that all accessible
airways distal to the mainstem bronchi between 3 and 10 mm in
diameter (excluding the right middle lobe) are treated. Currently
there are ongoing studies with the right middle lobe being treated
with BT, but at this time it is recommended that the right
middle lobe be left untreated. A strategic and systematic
approach, moving from distal to proximal within an airway while
also being cognizant of already treated airways, is essential.
Sedation and anesthesia should be personalized to each individ-
ual patient and be within the guidelines of each institution.
Although moderate sedation with midazolam and fentanyl is
commonly used, propofol has also been favored as an alternative
to midazolam. The use of total intravenous anesthesia with
propofol and minimal short-acting narcotics and anxiolytics
provides for a fast, efficient, and safe procedure and quicker
postprocedure recovery.
Intense postprocedural follow-up
An intense structured approach to postprocedural care, which
includes postprocedural outpatient follow-up and education on
early identification and management of complications after BT,
assists in efficient and comprehensive management with a unified
goal on quality and patient safety. A BT aftercare sheet that is given
to patients is essential in providing the necessary patient education
on identifying postprocedural complications along with when and
how to seek help (Figure 5). It is recommended that patients be
contacted 24 hours, 48 hours, and 7 days after the procedure to
assess their respiratory well-being. Postprocedure communication
should be personalized for each individual patient who receives BT
(ie, some patients may need to be contacted more frequently vs
others). Dynamic postprocedure communication (ie, how the
patient tolerated the procedure, adverse events during and after the
procedure) should also occur between the referring physician or
FIGURE 6. Dynamic communication after the procedure between the referring physician, BT performing physician, and patient. Patient
follow-up and communication (green arrow) occurs between each bronchial thermoplasty (BT) procedure with subsequent communi-
cation back to the referring physician after that visit before the next BT treatment. LLL, Left lower lobe; LUL, left upper lobe; RLL, right
lower lobe; RUL, right upper lobe.
TABLE IX. Clinical pearls—postprocedure care
 Follow institutional guidelines for routine postbronchoscopy care
 Administer nebulized bronchodilators with a frequent PRN basis
(some centers report as frequent as q15 min)
 Consider hospitalization if post-BT FEV1 < 80% of pre-BT FEV1
 Airway clearance device and nebulized bronchodilators the first few
days after BT
 Provide after care handout with instructions and emergency contact
numbers
BT, Bronchial thermoplasty; FEV1, forced expiratory volume in 1 s; PRN, as needed.
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asthmatologist, procedure performing bronchoscopist, and the
patient (Figures 5 and 6).
CONCLUSIONS
BT is not a cure for asthma; the decision to pursue BT should be
based on an appropriate clinical history, atopic tests, laboratory
findings, prior treatment response (ie, prior conventional medical
therapy and/or asthma biologic failure), and realistic goals of pa-
tients and clinicians (ie, reduce emergency department visits,
reduce exacerbations). A multitude of questions remain in asthma
treatment, especially when trying to decide which personalized
treatment will best benefit an individual patient’s specific asthma
endotype or phenotype. Irrespective of all the novel therapies
(biologic and nonbiologic) available for treating the varying
asthma subtypes, asthma control will continue to be suboptimal
until comorbidities, avoidable and unavoidable environmental
exposures, and adherence to standard therapies are adequately
addressed. With a decade of BT research and clinical experience,
we can state that BT is of unequivocal benefit and has an acceptable
safety profile. The difficulties and success of BT rest with imple-
menting an individualized BT plan using the three “I”s: (1)
identifying the right patient, (2) implementing the proper BT
technique, and (3) intense postprocedural care and follow-up.
REFERENCES
1. Mayse M, Laviolette M, Rubin AS, Lampron N, Simoff M, Duhamel D, et al.
Clinical pearls for bronchial thermoplasty. J Bronchology Interv Pulmonol
2007;14:115-23.
2. Chakir J, Haj-Salem I, Gras D, Joubert P, Beaudoin EL, Biardel S, et al. Effects
of bronchial thermoplasty on airway smooth muscle and collagen deposition in
asthma. Ann Am Thorac Soc 2015;12:1612-8.
3. Pretolani M, Dombret MC, Thabut G, Knap D, Hamidi F, Debray MP, et al.
Reduction of airway smooth muscle mass by bronchial thermoplasty in patients
with severe asthma. Am J Respir Crit Care Med 2014;190:1452-4.
4. Pretolani M, Bergqvist A, Thabut G, Dombret MC, Knapp D, Hamidi F, et al.
Effectiveness of bronchial thermoplasty in patients with severe refractory
asthma: clinical and histopathologic correlations. J Allergy Clin Immunol 2017;
139:1176-85.
5. Danek CJ, Lombard CM, Dungworth DL, Cox PG, Miller JD, Biggs MJ, et al.
Reduction in airway hyperresponsiveness to methacholine by the application of
RF energy in dogs. J Appl Physiol (1985) 2004;97:1946-53.
6. Cox G, Thomson NC, Rubin AS, Niven RM, Corris PA, Siersted HC, et al.
Asthma control during the year after bronchial thermoplasty. N Engl J Med
2007;356:1327-37.
7. Pavord ID, Cox G, Thomson NC, Rubin AS, Corris PA, Niven RM, et al. Safety
and efficacy of bronchial thermoplasty in symptomatic, severe asthma. Am J
Respir Crit Care Med 2007;176:1185-91.
8. Castro M, Rubin AS, Laviolette M, Fiterman J, De Andrade Lima M, Shah PL,
et al. Effectiveness and safety of bronchial thermoplasty in the treatment of
severe asthma: a multicenter, randomized, double-blind, sham-controlled clin-
ical trial. Am J Respir Crit Care Med 2010;181:116-24.
9. Chupp G, Laviolette M, Cohn L, McEvoy C, Bansal S, Shifren A, et al. Long-
term outcomes of bronchial thermoplasty in subjects with severe asthma: a
comparison of 3-year follow-up results from two prospective multicentre
studies. Eur Respir J 2017;50:1700017.
10. Chung KF, Wenzel SE, Brozek JL, Bush A, Castro M, Sterk PJ, et al. Inter-
national ERS/ATS guidelines on definition, evaluation and treatment of severe
asthma. Eur Respir J 2014;43:343-73.
11. Chung KF, Wenzel SE, Brozek JL. ERS/ATS Task Force on Definition,
Evaluation and Treatment of Severe Asthma. From the authors. Eur Respir J
2014;44:267-8.
12. Cox G, Miller JD, McWilliams A, Fitzgerald JM, Lam S. Bronchial thermo-
plasty for asthma. Am J Respir Crit Care Med 2006;173:965-9.
13. Cox PG, Miller J, Mitzner W, Leff AR. Radiofrequency ablation of airway
smooth muscle for sustained treatment of asthma: preliminary investigations.
Eur Respir J 2004;24:659-63.
14. Gudmundsson G, Gross TJ. Middle lobe syndrome. Am Fam Physician 1996;
53:2547-50.
15. Thomen RP, Sheshadri A, Quirk JD, Kozlowski J, Ellison HD, Szczesniak RD,
et al. Regional ventilation changes in severe asthma after bronchial thermoplasty
with (3)He MR imaging and CT. Radiology 2015;274:250-9.
16. Langton D, Sha J, Ing A, Fielding D, Thien F, Plummer V. Bronchial ther-
moplasty: activations predict response. Respir Res 2017;18:134.
17. Doeing DC, Mahajan AK, White SR, Naureckas ET, Krishnan JA, Hogarth DK.
Safety and feasibility of bronchial thermoplasty in asthma patients with very
severe fixed airflow obstruction: a case series. J Asthma 2013;50:215-8.
18. Bel EH, Sousa A, Fleming L, Bush A, Chung KF, Versnel J, et al. Diagnosis
and definition of severe refractory asthma: an international consensus statement
from the Innovative Medicine Initiative (IMI). Thorax 2011;66:910-7.
19. Global Initiative for Asthma (GINA). Global Strategy for Asthma Management
and Prevention. Updated 2018. Available from: https://ginasthma.org/2018-
gina-report-global-strategy-for-asthma-management-and-prevention/. Accessed
September 20, 2018.
20. Antoniades N, Worsnop C. Topical lidocaine through the bronchoscope reduces
cough rate during bronchoscopy. Respirology 2009;14:873-6.
21. Langmack EL, Martin RJ, Pak J, Kraft M. Serum lidocaine concentrations in
asthmatics undergoing research bronchoscopy. Chest 2000;117:1055-60.
22. Wolfe JW, Butterworth JF. Local anesthetic systemic toxicity: update on
mechanisms and treatment. Curr Opin Anaesthesiol 2011;24:561-6.
23. Moore DC, Green J. Systemic toxic reactions to local anesthetics. Calif Med
1956;85:70-4.
24. Chadha M, Kulshrestha M, Biyani A. Anaesthesia for bronchoscopy. Indian J
Anaesth 2015;59:565-73.
25. Matot I, Kramer MR. Sedation in outpatient bronchoscopy. Respir Med 2000;
94:1145-53.
26. Kahn KS, Hayes I, Buggy DJ. Pharmacology of anaesthetic agents I: intrave-
nous anaesthetic agents. CEACCP 2014;14:100-5.
27. Wahidi MM, Jain P, Jantz M, Lee P, Mackensen GB, Barbour SY, et al.
American College of Chest Physicians consensus statement on the use of topical
anesthesia, analgesia, and sedation during flexible bronchoscopy in adult pa-
tients. Chest 2011;140:1342-50.
28. d’Hooghe JNS, Bonta PI, van den Berk IAH, Annema JT. Radiological ab-
normalities following bronchial thermoplasty: is the pathophysiology under-
stood? Eur Respir J 2017;50:1701537.
J ALLERGY CLIN IMMUNOL PRACT
JANUARY 2019
80 TAN ETAL
